Tamoxifen reduces hepatic VLDL production and GH secretion in women: A possible mechanism for steatosis development

Vita Birzniece, P. Hugh R. Barrett, Ken K.Y. Ho

Research output: Contribution to journalArticle

7 Citations (Scopus)
105 Downloads (Pure)

Abstract

Context: Growth hormone (GH) stimulates hepatic synthesis of very-low-density lipoproteins (VLDL), whereas hepatic steatosis develops as a result of GH deficiency. Steatosis is also a complication of tamoxifen treatment, the cause of which is not known. As tamoxifen inhibits the secretion and action of GH, we hypothesize that it induces steatosis by inhibiting hepatic VLDL export. Aim: To investigate whether tamoxifen reduces hepatic VLDL secretion. Design: Eight healthy, normolipidemic women (age: 64.4 ± 2.1 years) were studied in random sequence at baseline, after 2 weeks of tamoxifen (20 mg/day) and after 2 weeks of estradiol valerate (EV; 2 mg/day) treatments, separated by a 4-week washout period. The kinetics of apolipoprotein B (apoB), the structural protein of VLDL particles, were measured using a stable isotope 2H3-leucine turnover technique. VLDL-apoB fractional catabolic rate (FCR) was determined using a multicompartment model. VLDL-apoB secretion was estimated as the product of FCR and VLDL-apoB concentration. GH response to arginine stimulation, circulating levels of IGF-1, FFA, and TG, along with TG content in VLDL were measured. Results: Tamoxifen significantly (P < 0.05) reduced VLDL-apoB concentration and secretion by 27.3 ± 7.8% and 29.8 ± 10.2%, respectively. In contrast, EV did not significantly change VLDL-apoB concentration or secretion. Tamoxifen but not EV significantly reduced (P < 0.05) GH response to arginine stimulation. Both treatments significantly lowered (P < 0.05) circulating IGF-1. Conclusion: Inhibition of VLDL secretion may contribute to the development of fatty liver during tamoxifen therapy. As GH stimulates VLDL secretion, the development of steatosis may arise secondarily from GH insufficiency induced by tamoxifen.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalEuropean Journal of Endocrinology
Volume177
Issue number2
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

VLDL Lipoproteins
Tamoxifen
Growth Hormone
Liver
Apolipoproteins B
estradiol valerate
Insulin-Like Growth Factor I
Arginine
Fatty Liver
Therapeutics
Leucine
Isotopes

Cite this

@article{312872e88b5a46059494c7f8057f9dff,
title = "Tamoxifen reduces hepatic VLDL production and GH secretion in women: A possible mechanism for steatosis development",
abstract = "Context: Growth hormone (GH) stimulates hepatic synthesis of very-low-density lipoproteins (VLDL), whereas hepatic steatosis develops as a result of GH deficiency. Steatosis is also a complication of tamoxifen treatment, the cause of which is not known. As tamoxifen inhibits the secretion and action of GH, we hypothesize that it induces steatosis by inhibiting hepatic VLDL export. Aim: To investigate whether tamoxifen reduces hepatic VLDL secretion. Design: Eight healthy, normolipidemic women (age: 64.4 ± 2.1 years) were studied in random sequence at baseline, after 2 weeks of tamoxifen (20 mg/day) and after 2 weeks of estradiol valerate (EV; 2 mg/day) treatments, separated by a 4-week washout period. The kinetics of apolipoprotein B (apoB), the structural protein of VLDL particles, were measured using a stable isotope 2H3-leucine turnover technique. VLDL-apoB fractional catabolic rate (FCR) was determined using a multicompartment model. VLDL-apoB secretion was estimated as the product of FCR and VLDL-apoB concentration. GH response to arginine stimulation, circulating levels of IGF-1, FFA, and TG, along with TG content in VLDL were measured. Results: Tamoxifen significantly (P < 0.05) reduced VLDL-apoB concentration and secretion by 27.3 ± 7.8{\%} and 29.8 ± 10.2{\%}, respectively. In contrast, EV did not significantly change VLDL-apoB concentration or secretion. Tamoxifen but not EV significantly reduced (P < 0.05) GH response to arginine stimulation. Both treatments significantly lowered (P < 0.05) circulating IGF-1. Conclusion: Inhibition of VLDL secretion may contribute to the development of fatty liver during tamoxifen therapy. As GH stimulates VLDL secretion, the development of steatosis may arise secondarily from GH insufficiency induced by tamoxifen.",
author = "Vita Birzniece and Barrett, {P. Hugh R.} and Ho, {Ken K.Y.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1530/EJE-17-0151",
language = "English",
volume = "177",
pages = "137--143",
journal = "European Journal of Endocrinology,",
issn = "0804-4643",
publisher = "BioScientifica Ltd",
number = "2",

}

Tamoxifen reduces hepatic VLDL production and GH secretion in women : A possible mechanism for steatosis development. / Birzniece, Vita; Barrett, P. Hugh R.; Ho, Ken K.Y.

In: European Journal of Endocrinology, Vol. 177, No. 2, 01.08.2017, p. 137-143.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tamoxifen reduces hepatic VLDL production and GH secretion in women

T2 - A possible mechanism for steatosis development

AU - Birzniece, Vita

AU - Barrett, P. Hugh R.

AU - Ho, Ken K.Y.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Context: Growth hormone (GH) stimulates hepatic synthesis of very-low-density lipoproteins (VLDL), whereas hepatic steatosis develops as a result of GH deficiency. Steatosis is also a complication of tamoxifen treatment, the cause of which is not known. As tamoxifen inhibits the secretion and action of GH, we hypothesize that it induces steatosis by inhibiting hepatic VLDL export. Aim: To investigate whether tamoxifen reduces hepatic VLDL secretion. Design: Eight healthy, normolipidemic women (age: 64.4 ± 2.1 years) were studied in random sequence at baseline, after 2 weeks of tamoxifen (20 mg/day) and after 2 weeks of estradiol valerate (EV; 2 mg/day) treatments, separated by a 4-week washout period. The kinetics of apolipoprotein B (apoB), the structural protein of VLDL particles, were measured using a stable isotope 2H3-leucine turnover technique. VLDL-apoB fractional catabolic rate (FCR) was determined using a multicompartment model. VLDL-apoB secretion was estimated as the product of FCR and VLDL-apoB concentration. GH response to arginine stimulation, circulating levels of IGF-1, FFA, and TG, along with TG content in VLDL were measured. Results: Tamoxifen significantly (P < 0.05) reduced VLDL-apoB concentration and secretion by 27.3 ± 7.8% and 29.8 ± 10.2%, respectively. In contrast, EV did not significantly change VLDL-apoB concentration or secretion. Tamoxifen but not EV significantly reduced (P < 0.05) GH response to arginine stimulation. Both treatments significantly lowered (P < 0.05) circulating IGF-1. Conclusion: Inhibition of VLDL secretion may contribute to the development of fatty liver during tamoxifen therapy. As GH stimulates VLDL secretion, the development of steatosis may arise secondarily from GH insufficiency induced by tamoxifen.

AB - Context: Growth hormone (GH) stimulates hepatic synthesis of very-low-density lipoproteins (VLDL), whereas hepatic steatosis develops as a result of GH deficiency. Steatosis is also a complication of tamoxifen treatment, the cause of which is not known. As tamoxifen inhibits the secretion and action of GH, we hypothesize that it induces steatosis by inhibiting hepatic VLDL export. Aim: To investigate whether tamoxifen reduces hepatic VLDL secretion. Design: Eight healthy, normolipidemic women (age: 64.4 ± 2.1 years) were studied in random sequence at baseline, after 2 weeks of tamoxifen (20 mg/day) and after 2 weeks of estradiol valerate (EV; 2 mg/day) treatments, separated by a 4-week washout period. The kinetics of apolipoprotein B (apoB), the structural protein of VLDL particles, were measured using a stable isotope 2H3-leucine turnover technique. VLDL-apoB fractional catabolic rate (FCR) was determined using a multicompartment model. VLDL-apoB secretion was estimated as the product of FCR and VLDL-apoB concentration. GH response to arginine stimulation, circulating levels of IGF-1, FFA, and TG, along with TG content in VLDL were measured. Results: Tamoxifen significantly (P < 0.05) reduced VLDL-apoB concentration and secretion by 27.3 ± 7.8% and 29.8 ± 10.2%, respectively. In contrast, EV did not significantly change VLDL-apoB concentration or secretion. Tamoxifen but not EV significantly reduced (P < 0.05) GH response to arginine stimulation. Both treatments significantly lowered (P < 0.05) circulating IGF-1. Conclusion: Inhibition of VLDL secretion may contribute to the development of fatty liver during tamoxifen therapy. As GH stimulates VLDL secretion, the development of steatosis may arise secondarily from GH insufficiency induced by tamoxifen.

UR - http://www.scopus.com/inward/record.url?scp=85023202566&partnerID=8YFLogxK

U2 - 10.1530/EJE-17-0151

DO - 10.1530/EJE-17-0151

M3 - Article

VL - 177

SP - 137

EP - 143

JO - European Journal of Endocrinology,

JF - European Journal of Endocrinology,

SN - 0804-4643

IS - 2

ER -